Home Health M&A Is Rebounding After 4 Years of Decline: Why This Seller's Window Is Opening Now

Home health and hospice M&A is gaining momentum after four years of decline. Certified home health and hospice transactions are leading the rebound while CMS payment expectations become more predictable and the enrollment moratorium limits new entrants. This article explains how scarcity, compliance, and durable EBITDA may affect sale price for owners in the $2 million to $10 million revenue range. It also provides practical steps for preparing your agency for a direct acquisition or strategic partnership.

8/27/20267 min read

After four consecutive years of decline, home health and hospice dealmaking is gaining momentum. For owners in the $2 million to $10 million revenue range, stronger buyer interest, limited access to new provider numbers, and a more predictable Medicare payment outlook are creating a potential seller’s window.

Quick Scan Summary

Who this is for

Home health or hospice owners with $2 million to $10 million in annual revenue
Founders considering a sale, succession plan, or strategic partnership
Operators who want to understand how CMS policy and buyer competition affect sale price
Owners who need time to improve compliance, margins, staffing, and leadership depth before a transaction

Key takeaways

The Braff Group’s annualized first half data points to 134 transactions in 2026 across certified home health, hospice, private duty, and Medicaid categories, up 12.6 percent from 119 transactions in 2025.
Certified home health is on pace for 48 deals, up 41 percent, while hospice is on pace for 44 deals, up 57 percent.
CMS proposed a 2.4 percent aggregate increase in CY 2027 home health payments, or approximately $420 million.
The nationwide enrollment moratorium limits new HHA and hospice enrollments and certain non exempt changes in majority ownership.
Scarcity can support stronger multiples, but only for agencies with clean provider numbers, defensible earnings, reliable staffing, and manageable compliance risk.

Market Context: Buyers Are Coming Back, but They Are Still Selective

The rebound is not a return to the undisciplined deal market of earlier years. Buyers are returning with more capital and clearer acquisition strategies, but their underwriting remains focused on cash flow durability, compliance, payer risk, and the agency’s ability to operate after the owner steps away.

Home Health Care News reported that dealmaking is gaining momentum after a prolonged decline. The article cited Braff Group data showing an annualized first half pace of 134 transactions in 2026 across several care categories, compared with 119 in 2025.

That improvement matters because transaction volume influences buyer urgency. When fewer agencies come to market, quality assets receive more attention. When buyer demand rises at the same time, owners with clean operations may have more leverage over structure, timing, and price.

The opportunity is especially notable in certified home health and hospice. Private duty transactions are down 10 percent, and Medicaid transactions are down 42 percent. This makes the growth in certified home health and hospice more meaningful because it shows that buyer appetite is concentrating around certain regulated, licensed, and strategically valuable assets.

The Deal Data Owners Should Watch

The figures above represent different categories tracked in the report. They should not be added together as separate market totals because the 134 transaction figure is the combined annualized point.

For home health owners, the 48 deal pace signals renewed interest in certified provider platforms. For hospice owners, the 44 deal pace shows even stronger year over year growth. Both sectors can benefit from scarcity, but each requires a different underwriting lens. Home health buyers may focus heavily on payer mix, visit economics, authorization management, and clinical productivity. Hospice buyers may place greater emphasis on census durability, length of stay, referral diversity, live discharge patterns, and compliance history.

Why the Seller’s Window Is Forming

1. CMS payment expectations are more predictable

The CMS CY 2027 Home Health PPS Proposed Rule, CMS 1844 P, proposes a 2.4 percent aggregate increase in Medicare payments to home health agencies, estimated at approximately $420 million.

The proposal includes:

A 2.1 percent payment update
A proposed 3.0 percent temporary adjustment connected to recoupment of retrospective overpayments
PDGM case mix recalibration
Updates to outlier payment calculations and LUPA thresholds
Discussion of palliative care under the Medicare home health benefit

This outlook is more constructive than the prior payment cycle. Last year’s proposed reduction of 6.4 percent was widely viewed by operators as devastating before CMS finalized a 1.3 percent cut. The current proposal does not eliminate reimbursement risk, but it gives buyers a clearer basis for forecasting future cash flow.

Predictability matters in an acquisition. A buyer can underwrite a business more confidently when reimbursement assumptions are less volatile. That can support a stronger offer for agencies with reliable payer data and disciplined operating margins.

2. The enrollment moratorium increases scarcity

CMS implemented a nationwide enrollment moratorium for HHAs and hospices on May 13, 2026. The restriction applies to initial applications, including non exempt changes in majority ownership that require initial enrollment under the applicable rules.

The moratorium is scheduled to remain in effect for six months and may be extended in additional six month increments. Some market participants expect an extension in November, but CMS has not committed to extending it.

The practical effect is straightforward. New entrants cannot easily create a new Medicare enrolled HHA or hospice. Certain ownership transactions can also face additional complications if they trigger a new enrollment requirement.

That makes existing agencies more valuable, especially when they have:

An active and compliant provider number
A stable survey and accreditation record
A defensible service area
An experienced clinical team
Financial records that support normalized EBITDA

The moratorium does not make every agency more valuable. It increases the value of scarce, usable, and compliant assets.

3. Compliance risk is becoming more expensive

The CY 2027 proposed rule would allow all Medicare enrollment revocations to take effect retroactively to the date noncompliance began. CMS also proposed new or expanded denial and revocation bases involving majority ownership changes, license suspensions, and owners or managing organizations.

For sellers, this means provider number quality is central to transaction value. A buyer will want to understand survey history, corrective action plans, ownership records, licenses, enrollment filings, billing practices, and any unresolved repayment exposure.

A clean provider number can support an efficient transaction. A questionable provider number can lead to a lower multiple, a larger escrow, an earn out, or a decision not to proceed.

What This Means for Sale Price and Buyer Underwriting

Competition and scarcity can create upward pressure on multiples, but the benefit flows first to agencies that reduce buyer risk.

Consider an illustrative home health or hospice agency with $800,000 of normalized EBITDA:

These are illustrative scenarios, not an appraisal or a statement of current market pricing. The difference between 4.5 times and 7 times EBITDA is $2 million on the same earnings base.

A composite example illustrates the point. Consider an owner who operates a $6 million hospice agency and wants to retire within two years. The agency has strong referral relationships, but 55 percent of admissions come from three sources, the owner approves most major staffing decisions, and payer level profitability is not tracked. The agency may attract buyer interest, but underwriters could treat concentration and key person dependence as risks.

If the owner documents leadership responsibilities, diversifies referrals, and produces consistent payer level reporting, the agency may become easier to underwrite. The goal is not to create a perfect business. The goal is to reduce uncertainty before the buyer prices that uncertainty into the offer.

The Buyer Dashboard to Build Now

Owners should track the same information a strategic buyer will request. For home health agencies, review these metrics monthly:

Net reimbursement per completed visit by payer
Authorized visits compared with clinically ordered visits
Denials and appeal overturn rates
Authorization labor hours per 100 Medicare Advantage episodes
Days in accounts receivable by payer
EBITDA margin by payer
Revenue concentration by individual Medicare Advantage plan
Referral volume by payer and referral source

Hospice owners should apply the same discipline to census trends, length of stay, live discharge rates, referral concentration, staffing coverage, and payer level margins.

When Should You Start Preparing?

The seller’s window may be opening, but that does not mean every owner should sell immediately. Timing depends on readiness.

Owners who wait until they receive an offer may have limited time to correct problems. Owners who begin now can establish a clean financial baseline, resolve documentation gaps, strengthen leadership coverage, and decide whether a sale or continued ownership best serves their goals.

So What Should You Do Now?

Prepare a buyer data room containing three years of financial statements, payer reports, census data, survey records, licenses, enrollment documents, and ownership history.
Review your provider number and every prior or planned change in majority ownership with qualified transaction counsel.
Build a monthly operating dashboard that shows payer economics, referral concentration, staffing stability, and normalized EBITDA.
Speak directly with Senate Healthcare if you want to explore a sale or strategic partnership with an acquiring organization before your agency is perfectly positioned.

Plain Language Glossary

EBITDA: A measure of operating earnings before interest, taxes, depreciation, and amortization.

Valuation multiple: The number applied to EBITDA to estimate enterprise value. For example, $800,000 of EBITDA at 6 times equals $4.8 million.

Provider number: The Medicare enrollment identity that allows an eligible agency to participate and bill in the program.

CIMO: A change in majority ownership. Certain non exempt changes can require an agency to enroll as a new provider.

Buyer underwriting: The process of testing whether an agency’s earnings, compliance position, staffing, and growth prospects are reliable enough to support a purchase price.

Earn out: A portion of purchase consideration paid later if agreed performance conditions are met.

Normalized EBITDA: Earnings adjusted to remove unusual, personal, or nonrecurring expenses so the buyer can evaluate ongoing operations.

A Direct Path to Senate Healthcare

Senate Healthcare is the buyer and strategic partner pursuing acquisitions of home health or hospice agencies. We are evaluating opportunities where an owner wants to protect the continuity of care, reduce transition risk, and create a practical path for growth or succession.

Your agency does not need to be perfect to begin a direct conversation. If you are considering a sale, retirement, or partnership, now is the time to understand how a buyer will evaluate your provider number, earnings, leadership depth, and operating risks.

Resources:

Unlock Your 30-Minute Agency Succession Review

Maybe you're ready to expand your reach, or perhaps it's time to consider your legacy and the future of your business. Either way, it all begins with a conversation. Schedule a confidential, no-obligation call to explore what the future might hold for you and your business.

Complete the form, and we'll reach out for a chat...